問卷

TPIDB > Search Result

Search Result

篩選

List

115Cases

2025-03-31 - 2028-06-30

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2025-06-01 - 2034-08-15

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-08-26 - 2026-07-23

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-11-01 - 2026-03-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2022-02-07 - 2022-08-31

Phase I

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting2Sites

Terminated1Sites

2024-01-01 - 2025-09-30

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-10-02 - 2026-11-01

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients
  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2016-03-15 - 2018-03-15

Phase III

A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis
  • Condition/Disease

    Renal Anemia

  • Test Drug

    UB-851

Participate Sites
18Sites

Recruiting10Sites

Terminated8Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites